Skip to main content
SpringerLink
Log in

Novel oral anticoagulants and valvular atrial fibrillation: are they always contraindicated?

  • IM - REVIEW
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

Abstract

Atrial fibrillation (AF) is the most common sustained cardiac dysrhythmia, and is associated with an increased risk of death, stroke, and other thromboembolic events. Valvular heart disease (VHD) frequently coexists with AF, mostly in elderly patients. After the introduction of novel oral anticoagulants (NOACs) approved for the prevention of stroke in non-valvular atrial fibrillation (NVAF) on the basis of recent trials, the importance of a universal definition of NVAF was raised in clinical practice. In the most recent guidelines, the term valvular AF is used to imply that AF is related to rheumatic valvular disease (predominantly mitral stenosis), or prosthetic heart valves. In all the trials comparing NOACs and warfarin, a significant percentage of patients presented any type of VHD, excluding rheumatic mitral stenosis and mechanical heart valve. The subgroups analysis performed, so far showed no significant differences in terms of efficacy in the VHD subgroup compared to the general AF population. A restrictive definition of valvular AF (i.e., rheumatic mitral stenosis and mechanical heart valve) seems to be the most appropriate to contraindicate treatment with NOACs for AF thromboprophylaxis. In the remaining AF patients with significant valvular disease who per se would not require oral anticoagulation, NOACs should be allowed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Camm AJ, Lip GY, De Caterina R et al (2012) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Europace 14:1385–1413

    Article  PubMed  Google Scholar 

  2. Raviele A, Disertori M, Alboni P et al (2013) Linee guida AIAC per la gestione e il trattamento della fibrillazione atriale. Aggiornamento 2013. G Ital Cardiol 14:215–240

    Google Scholar 

  3. Hart RG, Pearce LA, Aguilar MI (2007) Meta-analysis: antithrombotic therapy to prevent stroke in patients who have non-valvular atrial fibrillation. Ann Intern Med 146:857–867

    Article  PubMed  Google Scholar 

  4. Lip YH, Nieuwlaat R, Pisters R et al (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach. The euro heart survey on atrial fibrillation. Chest 137(2):263–272

    Article  PubMed  Google Scholar 

  5. Kannel WB, Abbott RD, Savage DD, McNamara PM (1982) Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 306:1018–1022

    Article  CAS  PubMed  Google Scholar 

  6. Kirchhof P, Ammentorp B, Darius H, De Caterina R et al (2014) Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboembolic events—European Registry in Atrial Fibrillation (PREFER in AF). Europace 16:6–14

    Article  PubMed Central  PubMed  Google Scholar 

  7. Nieuwlaat R, Capucci A, Camm J, Olsson SB, Andresen D, Davies DW et al (2005) Atrial fibrillation management: a prospective survey in ESC Member Countries. The Euro Heart Survey on Atrial Fibrillation. Eur Heart J 26:2422–2434

    Article  PubMed  Google Scholar 

  8. Molteni M, Friz HP, Primitz L et al (2014) The definition of valvular and non-valvular atrial fibrillation: results of a physicians’ survey. Europace. doi:10.1093/europace/euu178

    PubMed  Google Scholar 

  9. Lip GY, Laroche C, Dan GA, Santini M, Kalarus Z, Rasmussen LH et al (2014) A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of Euro Observational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace 16:308–319

    Article  PubMed  Google Scholar 

  10. Di Pasquale G, Mathieu G, Maggioni AP et al (2013) On behalf of ATA-AF Investigators. Current presentation and management of 7,148 patients with atrial fibrillation in cardiology and internal medicine hospital centers: The ATA AF study. Int J Cardiol 167:2895–2903

    Article  PubMed  Google Scholar 

  11. Gussoni G, Di Pasquale G, Vescovo G et al (2013) Decision making for oral anticoagulants in atrial fibrillation: the ATA-AF study. Eur J Intern Med 24:324–332

    Article  PubMed  Google Scholar 

  12. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. (2009) RE-LY Steering Committee and Investigators. Dabigatran vs. warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–51

  13. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al. ROCKET-AF Investigators (2011) Rivaroxaban vs. warfarin in non-valvular atrial fibrillation. N Engl J Med 365:883–91

  14. Connolly SJ, Eikelboom J, Joyner C et al. on behalf of AVERROES Steering Committee and Investigators (2011) Apixaban in patients with atrial fibrillation. N Engl J Med 2011 Mar 3;364:806–817

  15. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M et al. ARISTOTLE Committees and Investigators (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992

  16. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL et al. ENGAGE AF-TIMI 48 Investigators (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369:2093–2104

  17. Ezekowitz MD, Parise H, Nagarakanti R et al. (2014) Abstract “Innovation and Intervention” of the American College of Cardiology

  18. Breithardt G, Baumgartner H, Berkowitz SD et al. (2014) Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. Eur Heart J (Epub ahead of print)

  19. Avezum A, Lopes RD, Schulte PJ et al. Apixaban versus warfarin in patients with atrial fibrillation and valvular heart disease: findings from the ARISTOTLE study. Abstract 4384, ESC Congress 2013

  20. Blustin JM, McBane RD, Ketha SS et al (2014) Distribution of thromboembolism in valvular versus non-valvular atrial fibrillation. Expert Rev Cardiovasc Ther 12:1129–1132

    Article  CAS  PubMed  Google Scholar 

  21. Mahajan R, Brooks AG, Sullivan T et al (2012) Importance of the underlying substrate in determining thrombus location in atrial fibrillation: implications for left atrial appendage closure. Heart 98:1120–1126

    Article  PubMed  Google Scholar 

  22. Luis SA, Poon K, Luis C, Shukla A, Bett N, Hamilton-Craig C (2013) Massive left atrial thrombus in a patient with rheumatic mitral stenosis and atrial fibrillation while anticoagulated with dabigatran. Circ Cardiovasc Imaging 6:491–492

    Article  PubMed  Google Scholar 

  23. Eikelboom JW, Connoly SJ, Brueckmann M et al. for the RE-ALIGN Investigators (2013) Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 369:1206–1214

  24. The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC), The European Association for Cardio-Thoracic Surgery (EACTS) (2012) Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 33:2451–2496

    Article  Google Scholar 

Download references

Conflict of interest

Giuseppe Di Pasquale, M.D. received honoraria for lectures (congresses' participation and meetings with didactic purpouses) from Boehringer-Ingelheim, Bayer, BMS/Pfizer, Daiichi-Sankyo.

Author information

Authors and Affiliations

  1. Unità Operativa di Cardiologia, Ospedale Maggiore, Largo Bartolo Nigrisoli, 2, 40133, Bologna, Italy

    Giuseppe Di Pasquale, Silvia Zagnoni & Letizia Riva

Authors
  1. Giuseppe Di Pasquale
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Silvia Zagnoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Letizia Riva
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giuseppe Di Pasquale.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Di Pasquale, G., Zagnoni, S. & Riva, L. Novel oral anticoagulants and valvular atrial fibrillation: are they always contraindicated?. Intern Emerg Med 10, 21–24 (2015). https://doi.org/10.1007/s11739-014-1181-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11739-014-1181-5

Keywords

Search

Navigation